Iovance Biotherapeutics (IOVA) Shares Outstanding (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Shares Outstanding (Entity) of $418511.0 for Q1 2026, up 29.62% year-over-year from $322868.0 in Q1 2025, and up 17.12% quarter-over-quarter from $357345.0 in Q4 2025.
Iovance Biotherapeutics (IOVA) Shares Outstanding (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Shares Outstanding (Entity) for 17 consecutive years, with $418511.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 29.62% year-over-year to $418511.0; the TTM figure through Mar 2026 stood at $418511.0 (up 29.62% YoY), while the FY2025 annual figure was $357345.0, up 23.27% from the prior year.
- Shares Outstanding (Entity) rose to $418511.0 in Q1 2026 per IOVA's latest filing, from $357345.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $279.8 million in Q1 2024 and bottomed at $157113.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $76.7 million across 5 years, with a median of $357345.0 in 2025.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 142701.03% — and 2025, when it slumped 99.88%.
- Iovance Biotherapeutics' Shares Outstanding (Entity) stood at $159259.0 in 2022, then soared by 47.64% to $235131.0 in 2023, then climbed by 23.28% to $289877.0 in 2024, then rose by 23.27% to $357345.0 in 2025, then increased by 17.12% to $418511.0 in 2026.
- Business Quant data shows IOVA's Shares Outstanding (Entity) at $418511.0 in Q1 2026, $357345.0 in Q4 2025, and $364037.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 450.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 450,189.00 |
| Mar 31, 2026 | 418,511.00 |
| Dec 31, 2025 | 357,345.00 |
| Sep 30, 2025 | 364,037.00 |
| Jun 30, 2025 | 334,511.00 |
| Mar 31, 2025 | 322,868.00 |
| Dec 31, 2024 | 289,877.00 |
| Sep 30, 2024 | 303,269.00 |
| Jun 30, 2024 | 284,817.00 |
| Mar 31, 2024 | 266.22 Mn |
| Dec 31, 2023 | 235,131.00 |
| Sep 30, 2023 | 245.82 Mn |
| Jun 30, 2023 | 224.48 Mn |
| Mar 31, 2023 | 213.69 Mn |
| Dec 31, 2022 | 159,259.00 |
| Sep 30, 2022 | 157.82 Mn |
| Jun 30, 2022 | 157.27 Mn |
| Mar 31, 2022 | 157,113.00 |
| Dec 31, 2021 | 153,406.00 |
| Sep 30, 2021 | 155,508.00 |